A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
Public ClinicalTrials.gov record NCT03919162. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B. In Phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants. In the event that the stage gate for Phase 2B is reached, then Phase 2B will assesses efficacy and longer-term safety in a larger study group, i.e., 414.
Study identification
- NCT ID
- NCT03919162
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 89 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2021 (Actual)
- Primary completion
- Jul 12, 2024 (Actual)
- Completion
- Aug 12, 2024 (Actual)
- Last update posted
- Dec 12, 2025
2021 – 2024
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| Banner Sun Health Research Institute | Sun City | Arizona | 85351 | — |
| The Neuron Clinic | Chula Vista | California | 91910 | — |
| University of California | Irvine | California | 92868 | — |
| UCSD Alzheimer's Disease Research Center | La Jolla | California | 92037 | — |
| Cedars-Sinai Center | Los Angeles | California | 90048 | — |
| PCND Neurology | Poway | California | 92064 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20057 | — |
| USF Health Byrd Alzheimer's Center and Research Institute | Tampa | Florida | 33613 | — |
| Emory University | Atlanta | Georgia | 30329 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| The University of Iowa Carver College of Medicine | Iowa City | Iowa | 52242 | — |
| The University of Kentucky Sanders-Brown Center on Aging | Lexington | Kentucky | 40504 | — |
| Northern Light Acadia Hospital | Bangor | Maine | 04401 | — |
| NYU Langone Health Tisch Hospital | New York | New York | 10016 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| OHSU Neurology Clinic | Portland | Oregon | 97239 | — |
| Abington Neurological Associates | Abington | Pennsylvania | 19001 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Lowcountry Center for Veterans Research (LCVR) | Charleston | South Carolina | 29403 | — |
| UT Health San Antonio | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03919162, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03919162 live on ClinicalTrials.gov.